Sentinel node staging of primary melanoma by the "10% rule": pathology and clinical outcomes

Rachel E. Emery, Jeffrey Stevens, Robert Nance, Christopher Corless, John Vetto

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Surgical staging of clinically node-negative primary melanoma involves identification and removal of "sentinel" lymph nodes (SLNs). Although some suggest removal of only the "hottest" SLN, the "10% rule" dictates that nodes are removed until the background count is 10% or less of the count of the "hottest" node. Methods: To determine the utility of the 10% rule, a university database of clinically node-negative melanomas surgically staged by using this rule was examined. Results: Twenty-two of 177 cases (12.5%; 15% of T2 and T3 lesions) were SLN positive. Among the SLN-positive cases, use of the rule resulted in removal of 21 additional nodes, 7 of which contained tumor. In 3 cases (14%), the positive SLN was not the "hottest" node. At 49 months of mean follow-up time, overall survival was 63% for SLN-positive patients versus 92% for SLN-negative patients (P = .01). Conclusions: Sentinel node staging of melanoma by the 10% rule provides significant prognostic information and a modest increase in tumor detection compared with removal of only the "hottest" node.

Original languageEnglish (US)
Pages (from-to)618-622
Number of pages5
JournalAmerican Journal of Surgery
Volume193
Issue number5 SPEC. ISS.
DOIs
StatePublished - May 2007

Fingerprint

Clinical Pathology
Melanoma
cyhalothrin
Sentinel Lymph Node
Neoplasms
Databases
Survival

Keywords

  • 10% Rule
  • Melanoma
  • Sentinel lymph node

ASJC Scopus subject areas

  • Surgery

Cite this

Sentinel node staging of primary melanoma by the "10% rule" : pathology and clinical outcomes. / Emery, Rachel E.; Stevens, Jeffrey; Nance, Robert; Corless, Christopher; Vetto, John.

In: American Journal of Surgery, Vol. 193, No. 5 SPEC. ISS., 05.2007, p. 618-622.

Research output: Contribution to journalArticle

@article{d800f31ee1e446e68d21a09ab118f726,
title = "Sentinel node staging of primary melanoma by the {"}10{\%} rule{"}: pathology and clinical outcomes",
abstract = "Background: Surgical staging of clinically node-negative primary melanoma involves identification and removal of {"}sentinel{"} lymph nodes (SLNs). Although some suggest removal of only the {"}hottest{"} SLN, the {"}10{\%} rule{"} dictates that nodes are removed until the background count is 10{\%} or less of the count of the {"}hottest{"} node. Methods: To determine the utility of the 10{\%} rule, a university database of clinically node-negative melanomas surgically staged by using this rule was examined. Results: Twenty-two of 177 cases (12.5{\%}; 15{\%} of T2 and T3 lesions) were SLN positive. Among the SLN-positive cases, use of the rule resulted in removal of 21 additional nodes, 7 of which contained tumor. In 3 cases (14{\%}), the positive SLN was not the {"}hottest{"} node. At 49 months of mean follow-up time, overall survival was 63{\%} for SLN-positive patients versus 92{\%} for SLN-negative patients (P = .01). Conclusions: Sentinel node staging of melanoma by the 10{\%} rule provides significant prognostic information and a modest increase in tumor detection compared with removal of only the {"}hottest{"} node.",
keywords = "10{\%} Rule, Melanoma, Sentinel lymph node",
author = "Emery, {Rachel E.} and Jeffrey Stevens and Robert Nance and Christopher Corless and John Vetto",
year = "2007",
month = "5",
doi = "10.1016/j.amjsurg.2007.01.001",
language = "English (US)",
volume = "193",
pages = "618--622",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5 SPEC. ISS.",

}

TY - JOUR

T1 - Sentinel node staging of primary melanoma by the "10% rule"

T2 - pathology and clinical outcomes

AU - Emery, Rachel E.

AU - Stevens, Jeffrey

AU - Nance, Robert

AU - Corless, Christopher

AU - Vetto, John

PY - 2007/5

Y1 - 2007/5

N2 - Background: Surgical staging of clinically node-negative primary melanoma involves identification and removal of "sentinel" lymph nodes (SLNs). Although some suggest removal of only the "hottest" SLN, the "10% rule" dictates that nodes are removed until the background count is 10% or less of the count of the "hottest" node. Methods: To determine the utility of the 10% rule, a university database of clinically node-negative melanomas surgically staged by using this rule was examined. Results: Twenty-two of 177 cases (12.5%; 15% of T2 and T3 lesions) were SLN positive. Among the SLN-positive cases, use of the rule resulted in removal of 21 additional nodes, 7 of which contained tumor. In 3 cases (14%), the positive SLN was not the "hottest" node. At 49 months of mean follow-up time, overall survival was 63% for SLN-positive patients versus 92% for SLN-negative patients (P = .01). Conclusions: Sentinel node staging of melanoma by the 10% rule provides significant prognostic information and a modest increase in tumor detection compared with removal of only the "hottest" node.

AB - Background: Surgical staging of clinically node-negative primary melanoma involves identification and removal of "sentinel" lymph nodes (SLNs). Although some suggest removal of only the "hottest" SLN, the "10% rule" dictates that nodes are removed until the background count is 10% or less of the count of the "hottest" node. Methods: To determine the utility of the 10% rule, a university database of clinically node-negative melanomas surgically staged by using this rule was examined. Results: Twenty-two of 177 cases (12.5%; 15% of T2 and T3 lesions) were SLN positive. Among the SLN-positive cases, use of the rule resulted in removal of 21 additional nodes, 7 of which contained tumor. In 3 cases (14%), the positive SLN was not the "hottest" node. At 49 months of mean follow-up time, overall survival was 63% for SLN-positive patients versus 92% for SLN-negative patients (P = .01). Conclusions: Sentinel node staging of melanoma by the 10% rule provides significant prognostic information and a modest increase in tumor detection compared with removal of only the "hottest" node.

KW - 10% Rule

KW - Melanoma

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=34147182113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147182113&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2007.01.001

DO - 10.1016/j.amjsurg.2007.01.001

M3 - Article

C2 - 17434368

AN - SCOPUS:34147182113

VL - 193

SP - 618

EP - 622

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5 SPEC. ISS.

ER -